Antidepressant TOP10 reshuffle Green leaf class 1 new drugs are eye-catching

Since the beginning of this year, 6 varieties (27 specifications) of antidepressants have been approved
.
At present, there are 21 varieties that have been evaluated, of which the first imitation of Hausen Pharmaceutical has been approved this year
.
The latest data from Intranet shows that in the first half of 2022, the sales of terminal antidepressants in China's public medical institutions fell slightly year-on-year
.
TOP10 reshuffle, foreign companies "iron triangle" broke the game, domestic substitution accelerated, Lendbeck surpassed Pfizer to win the "first brother" throne, Jingwei Pharmaceutical advanced to the second place, and Haosen Pharmaceutical rose to the fourth place
.
Up to now, 23 antidepressants have been reported for production under review, and Luye Pharmaceutical's Class 1 new drugs are eye-catching, and Chengdu Kanghong Pharmaceutical| Chengdu Dikang Pharmaceutical, Yichang Renfu Pharmaceutical, CSPC Ouyi Pharmaceutical and other enterprises have sprinted to the
first in China.

 

Antidepressants broke out, and Hausen was the first to imitate it

 

Since the beginning of this year, antidepressants have been approved for marketing

Source: MED2.
0 China Drug Evaluation Database

 

Since the beginning of this year, 6 varieties (27 specifications) of antidepressants have been approved for marketing, among which escitalopram oxalate tablets, mirtazapine tablets, venlafaxine hydrochloride sustained-release capsules, and duloxetine hydrochloride enteric-coated capsules are the terminal TOP10 products
in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as China's public medical institutions) in the first half of 2022.

 

Antidepressant over-evaluation

Source: MED2.
0 China Drug Evaluation Database

 

Up to now, a total of 21 antidepressants have been evaluated, and escitalopram oxalate tablets and duloxetine hydrochloride enteric-coated capsules are popular varieties, and the number of evaluated companies is 11.

In addition, only 1 company of 8 varieties has been evaluated, among which Jiangsu Haosen Pharmaceutical's first imitation agomelatine tablet was approved in August this year with a supplementary application, becoming the first enterprise
to pass the evaluation of the product.
According to data from Intranet, the sales of agomelatine tablets in China's public medical institutions exceeded 500 million yuan in 2021, and continued to climb in the first half of 2022, up 46.
48%
year-on-year.

 

In terms of the number of evaluated varieties, Fosun Pharma has the most, with its subsidiaries Chongqing Yaoyou Pharmaceutical and Hunan Dongting Pharmaceutical having a total of 6 evaluations; Followed by Huahai Pharmaceutical with 4 reviews, Kelun Pharmaceutical, Fuyuan Pharmaceutical and Shanghai Shanghai Medicine Zhongxi Pharmaceutical each have 3 reviews
.

 

TOP10 big shuffle! The "iron triangle" of foreign enterprises has broken the situation, and domestic substitution has accelerated

 

Sales of terminal antidepressants in public medical institutions in China in recent years (100 million yuan)

Source: Terminal competition pattern of public medical institutions in China

 

According to statistics from the World Health Organization, more than 350 million people worldwide suffer from depression, with a growth rate of about 18%
in the past 10 years.
Depression has become a common disease in the world, and the related drug market has a huge space, and in China, the terminal of public medical institutions is the main sales channel
of antidepressants.
The latest data from Intranet shows that in the first half of 2022, the sales of terminal antidepressants in China's public medical institutions fell slightly year-on-year
.

 

With the normalization of centralized procurement and the continuous efforts of domestic pharmaceutical companies, the top position of the depressive drug market has been occupied by foreign-funded pharmaceutical companies for many years, and domestic substitution has further accelerated
.
From the perspective of the manufacturer pattern, the "iron triangle" situation composed of Pfizer, Eli Lilly and Lundbeck has been broken last year, and in the first half of this year, Ländbeck surpassed Pfizer and won the throne of "one brother", while Lilly slipped to seventh place
.
In addition, Shandong Dongwei Pharmaceutical has advanced to second place, Jiangsu Haosen Pharmaceutical has risen to fourth place, and the market share of domestic pharmaceutical companies such as Zhejiang Huahai Pharmaceutical and Renhetang Pharmaceutical is also rising
rapidly.

 

In the first half of 2022, China's public medical institutions had the top 10 terminal antidepressant products

Source: Terminal competition pattern of public medical institutions in China

 

The sales of TOP10 products have exceeded 100 million yuan, and escitalopram oxalate tablets still rank first
.
In terms of growth rate, agomelatine tablets are the fastest, more than 40%, trazodone hydrochloride tablets, fluvoxamine maleate tablets and mianserin hydrochloride tablets all exceed 20%.

 

At present, 8 antidepressants have been included in the collection, among which, escitalopram oxalate tablets, sertraline hydrochloride tablets, paroxetine hydrochloride tablets, venlafaxine hydrochloride sustained-release capsules, and duloxetine hydrochloride enteric-coated capsules are all in the
product TOP10.

 

In the first half of 2022, China's public medical institutions terminal antidepressant drug brand TOP10

Source: Terminal competition pattern of public medical institutions in China

 

Among the top 10 brands, 4 have sales of more than 200 million yuan, and the sales growth rate of the top three Shandong Dongwei Pharmaceutical's escitalopram oxalate tablets, Jiangsu Haosen Pharmaceutical Group's agomelatine tablets, and Lundbeck's escitalopram oxalate tablets have increased by more than 15%, while Pfizer's sertraline hydrochloride tablets have fallen by 20.
90%.

 

23 antidepressants are under review! Green leaf class 1 new drugs are eye-catching, Renfu, Kanghong .
.
.
Sprint to the first in China

 

There are no antidepressants approved by domestic enterprises and are under review

Source: MED2.
0 China Drug Evaluation Database

 

At present, there are 23 antidepressant applications under review, and more than 70 acceptance numbers
have been accepted.
Among them, vothioxetine hydrobromide tablets, venlafaxine hydrochloride sustained-release capsules, and escitalopram oxalate tablets are the most sought-after, and 4 companies have reported production
.

 

6 products, including escitalopram oxalate oral solution, milnacipran hydrochloride capsules, norvenlafaxine succinate sustained-release tablets, have not been approved, involving Chengdu Kanghong Pharmaceutical| Chengdu Dikang Pharmaceutical, Yichang Renfu Pharmaceutical, CSPC Group Ouyi Pharmaceutical and other enterprises
.
It is worth noting that Shandong Luye Pharmaceutical's Class 1 new drug Ansulfaxine hydrochloride sustained-release tablets (LY03005) is a new molecular entity therapeutic drug with a completely new mechanism of action, which is a triple reuptake inhibitor (SNDRI/TRI) of serotonin (5-HT), norepinephrine (NE)
and dopamine (DA).
。 In June this year, the company announced that the phase III clinical results of the product were released at the 2022 American Psychiatric Association (APA) annual meeting, highlighting its role and significance as China's original Class 1 new drug for the treatment of depression, and taking an important step
on the road to international academic recognition.

 

Source: Intranet database, company announcement

 

Note: Intranet's "Terminal Competition Pattern of China's Public Medical Institutions", the statistical scope is: China's urban public hospitals, county-level public hospitals, urban community centers and township health centers, excluding private hospitals, private clinics, and village clinics; The above sales are calculated
based on the average retail price of the product at the terminal.